Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04074434 · ClinicalTrials.gov registry record
Study Watch Atrial Fibrillation (AF) Detection Investigation
A clinical trial of Atrial Fibrillation, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 160
- Enrollment target
- 1
- Study location
NCT04074434: Completed study of Atrial Fibrillation, sponsored by Verily Life Sciences.
NCT04074434 is a study of Atrial Fibrillation that has completed, run by Verily Life Sciences. The registered enrollment target is 160 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04074434, a study of Atrial Fibrillation, has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 160 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, non-randomized study to refine the Study Watch's algorithm for AF detection within both persistent and paroxysmal AF subjects. The study will also collect data from an FDA-cleared wearable ECG sensor.
Primary Outcome
Sensitivity estimate for PPG irregular rhythm detection vs. a multi-lead Holter ECG rhythm
Conditions Studied
Interventions
- DEVICE Study Watch
Study Locations (1)
California
- San Diego Cardiac Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2018-11-12 |
| Est. Completion | 2019-07-22 |
What the finished NCT04074434 record still lists
NCT04074434 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Study Watch is the first listed.
NCT04074434 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04074434 about?
NCT04074434 is a clinical study titled "Study Watch Atrial Fibrillation (AF) Detection Investigation". This is a prospective, non-randomized study to refine the Study Watch's algorithm for AF detection within both persistent and paroxysmal AF subjects. The study will also collect data from an FDA-cleared wearable ECG sensor.
What is the current status of trial NCT04074434?
This trial is currently completed. The enrollment target is 160 participants. The study started on 2018-11-12. Estimated completion is 2019-07-22.
What conditions does trial NCT04074434 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT04074434?
The interventions under investigation include: Study Watch (DEVICE).
Who is sponsoring clinical trial NCT04074434?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04074434 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04074434's enrollment target sits among peer trials
160 117th of 202 higher than 86 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer
RECRUITING · Phase 2
-
The Dynamics of Human Atrial Fibrillation
RECRUITING
-
Renal Denervation + PVI vs PVI Alone for Persistent AF
RECRUITING · NA
-
Pericardiotomy in Cardiac Surgery
RECRUITING · NA
-
CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI